Related Articles for PubMed (Select 18485221)

Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors.

Sunami E, Shinozaki M, Sim MS, Nguyen SL, Vu AT, Giuliano AE, Hoon DS.

Breast Cancer Res. 2008;10(3):R46. Epub 2008 May 16.

PMID: 18485221 [PubMed - indexed for MEDLINE]

Related Articles Free article in PMC

How to target estrogen receptor-negative breast cancer?

Rochefort H, Glondu M, Sahla ME, Platet N, Garcia M.

Endocr Relat Cancer. 2003 Jun;10(2):261-6. Review.

PMID: 12790787 [PubMed - indexed for MEDLINE]

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.

Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ.

J Natl Cancer Inst. 2003 Jan 15;95(2):142-53.

PMID: 12529347 [PubMed - indexed for MEDLINE]

Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.

Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A.

Cancer. 2008 Mar 1;112(5):995-1000.

PMID: 18098228 [PubMed - indexed for MEDLINE]

FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.

Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4415-21.

PMID: 17671124 [PubMed - indexed for MEDLINE]

Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.

Bartlett JM, Ellis IO, Dowsett M, Mallon EA, Cameron DA, Johnston S, Hall E, A'Hern R, Peckitt C, Bliss JM, Johnson L, Barrett-Lee P, Ellis P.

J Clin Oncol. 2007 Oct 1;25(28):4423-30.

PMID: 17906205 [PubMed - indexed for MEDLINE]

10:

Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.

Fujii T, Kawahara A, Basaki Y, Hattori S, Nakashima K, Nakano K, Shirouzu K, Kohno K, Yanagawa T, Yamana H, Nishio K, Ono M, Kuwano M, Kage M.

Cancer Res. 2008 Mar 1;68(5):1504-12.

PMID: 18316615 [PubMed - indexed for MEDLINE]

11:

Do we need HER-2/neu testing for all patients with primary breast carcinoma?

Taucher S, Rudas M, Mader RM, Gnant M, Dubsky P, Bachleitner T, Roka S, Fitzal F, Kandioler D, Sporn E, Friedl J, Mittlböck M, Jakesz R.

Cancer. 2003 Dec 15;98(12):2547-53.

PMID: 14669272 [PubMed - indexed for MEDLINE]

12:

Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients.

Esteban JM, Felder B, Ahn C, Simpson JF, Battifora H, Shively JE.

Cancer. 1994 Sep 1;74(5):1575-83.

PMID: 7914825 [PubMed - indexed for MEDLINE]

13:

GSTP1 promoter haplotypes affect DNA methylation levels and promoter activity in breast carcinomas.

Rønneberg JA, Tost J, Solvang HK, Alnaes GI, Johansen FE, Brendeford EM, Yakhini Z, Gut IG, Lønning PE, Børresen-Dale AL, Gabrielsen OS, Kristensen VN.

Cancer Res. 2008 Jul 15;68(14):5562-71.

PMID: 18632608 [PubMed - indexed for MEDLINE]

14:

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R.

J Natl Cancer Inst. 2004 Jun 16;96(12):926-35.

PMID: 15199112 [PubMed - indexed for MEDLINE]

15:

HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.

Rydén L, Landberg G, Stål O, Nordenskjöld B, Fernö M, Bendahl PO.

Breast Cancer Res Treat. 2008 May;109(2):351-7. Epub 2007 Jul 18.

PMID: 17636399 [PubMed - indexed for MEDLINE]

16:

Prostate-specific antigen value as a marker in breast cancer.

Narita D, Cimpean AM, Anghel A, Raica M.

Neoplasma. 2006;53(2):161-7.

PMID: 16575473 [PubMed - indexed for MEDLINE]

17:

Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.

Wang-Rodriguez J, Cross K, Gallagher S, Djahanban M, Armstrong JM, Wiedner N, Shapiro DH.

Mod Pathol. 2002 Aug;15(8):853-61.

PMID: 12181271 [PubMed - indexed for MEDLINE]

18:

Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer.

Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, Berteloot P, Amant F, Vergote I, Christiaens MR.

Ann Oncol. 2005 Nov;16(11):1755-61. Epub 2005 Aug 5.

PMID: 16085689 [PubMed - indexed for MEDLINE]

19:

Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.

Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M, Stathopoulos EN, Stathopoulou A, Lianidou E, Chlouverakis G, Sotiriou C, Georgoulias V, Mavroudis D.

J Clin Oncol. 2007 Nov 20;25(33):5194-202. Epub 2007 Oct 22.

PMID: 17954712 [PubMed - indexed for MEDLINE]

20:

Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.

Hussein MR, Abd-Elwahed SR, Abdulwahed AR.

Cell Biol Int. 2008 Jun;32(6):698-707. Epub 2008 Jan 25.

PMID: 18296077 [PubMed - indexed for MEDLINE]

Recent Activity